First Time Loading...

Theseus Pharmaceuticals Inc
NASDAQ:THRX

Watchlist Manager
Theseus Pharmaceuticals Inc Logo
Theseus Pharmaceuticals Inc
NASDAQ:THRX
Watchlist
Price: 4.06 USD Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of THRX.

Key Points:
THRX Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Theseus Pharmaceuticals Inc's business.

What risks and challenges
does Theseus Pharmaceuticals Inc face in the near future?

Summarize the latest earnings report
of Theseus Pharmaceuticals Inc.

Provide P/E
for Theseus Pharmaceuticals Inc and its competitors.

Financials

Balance Sheet Decomposition
Theseus Pharmaceuticals Inc

Current Assets 209.6m
Cash & Short-Term Investments 205.1m
Other Current Assets 4.5m
Non-Current Assets 25m
Long-Term Investments 20.3m
PP&E 4.3m
Other Non-Current Assets 400k
Current Liabilities 7m
Accounts Payable 1.3m
Accrued Liabilities 5.3m
Other Current Liabilities 400k
Non-Current Liabilities 3.1m
Other Non-Current Liabilities 3.1m
Efficiency

Earnings Waterfall
Theseus Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-66.5m USD
Operating Income
-66.5m USD
Other Expenses
9.9m USD
Net Income
-56.6m USD

Free Cash Flow Analysis
Theseus Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

THRX Profitability Score
Profitability Due Diligence

Theseus Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Theseus Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

THRX Solvency Score
Solvency Due Diligence

Theseus Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Theseus Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

THRX Price Targets Summary
Theseus Pharmaceuticals Inc

Wall Street analysts forecast THRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for THRX is 5.25 USD .

Lowest
Price Target
Not Available
Average
Price Target
5.25 USD
29% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

THRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

THRX Price
Theseus Pharmaceuticals Inc

1M 1M
-
6M 6M
+51%
1Y 1Y
-50%
3Y 3Y
-78%
5Y 5Y
-78%
10Y 10Y
-78%
Annual Price Range
4.06
52w Low
2.12
52w High
11.82
Price Metrics
Average Annual Return -46.28%
Standard Deviation of Annual Returns 12.78%
Max Drawdown -89%
Shares Statistics
Market Capitalization 177m USD
Shares Outstanding 44 649 200
Percentage of Shares Shorted 1.91%

THRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Theseus Pharmaceuticals Inc Logo
Theseus Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

177m USD

Dividend Yield

0%

Description

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2021-10-07. The firm is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The firm is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The firm's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.

Contact

MASSACHUSETTS
Cambridge
245 Main Street
+18574009491.0
https://theseusrx.com/

IPO

2021-10-07

Employees

26

Officers

Co-Founder & Chairman
Dr. Iain D. Dukes DPHIL, M.A.
President, CFO & Director
Mr. Bradford D. Dahms
VP & Controller
Ms. Kristine Callahan CPA

See Also

Discover More